Published in Gastroenterology on December 07, 2011
Micro-computed tomography and nuclear magnetic resonance imaging for noninvasive, live-mouse cholangiography. Lab Invest (2013) 1.03
Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology (2013) 1.03
The role of the cilium in normal and abnormal cell cycles: emphasis on renal cystic pathologies. Cell Mol Life Sci (2012) 0.99
CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle (2012) 0.91
MicroRNAs in biliary diseases. World J Gastroenterol (2012) 0.87
Polycystic liver diseases: advanced insights into the molecular mechanisms. Nat Rev Gastroenterol Hepatol (2014) 0.87
Hepatic loss of miR-122 predisposes mice to hepatobiliary cyst and hepatocellular carcinoma upon diethylnitrosamine exposure. Am J Pathol (2013) 0.81
Role and regulation of Cdc25A phosphatase in neuron death induced by NGF deprivation or β-amyloid. Cell Death Discov (2016) 0.80
Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression. Am J Pathol (2013) 0.80
HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis. Am J Pathol (2014) 0.78
The zebrafish as a model to study polycystic liver disease. Zebrafish (2013) 0.77
Noninvasive monitoring of mouse renal allograft rejection using micro-CT. Ann Surg Treat Res (2015) 0.75
TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases via cAMP/Gαs signaling. Hepatology (2017) 0.75
Polycystic kidney disease. Annu Rev Med (2009) 4.78
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer (2007) 3.46
Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology (2006) 2.68
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2009) 2.33
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int (2005) 2.32
Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature (2006) 2.29
The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol (2006) 2.28
Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem (2004) 2.26
Novel agents on the horizon for cancer therapy. CA Cancer J Clin (2009) 2.11
Cdc25 phosphatases and cancer. Chem Biol (2004) 1.93
Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol (2005) 1.87
MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest (2008) 1.67
The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology (2009) 1.58
Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J Intern Med (2007) 1.54
Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease. Am J Pathol (2004) 1.49
A mouse model of autosomal recessive polycystic kidney disease with biliary duct and proximal tubule dilatation. Kidney Int (2007) 1.38
Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. Am J Pathol (2008) 1.34
The anticancer effects of vitamin K. Altern Med Rev (2003) 1.31
Somatostatin analogues reduce liver volume in polycystic liver disease. Gut (2008) 1.25
Cell cycle control by the CDC25 phosphatases. Anticancer Agents Med Chem (2008) 1.22
Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Res (2007) 1.20
Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD. Gastroenterology (2010) 1.20
Dual specificity protein phosphatases: therapeutic targets for cancer and Alzheimer's disease. Annu Rev Pharmacol Toxicol (2005) 1.18
Cholangiociliopathies: genetics, molecular mechanisms and potential therapies. Curr Opin Gastroenterol (2009) 1.17
PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther (2006) 1.02
Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry (2009) 0.98
Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer. Cancer Lett (2010) 0.98
Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review. Expert Opin Ther Pat (2010) 0.97
Hepato-renal pathology in pkd2ws25/- mice, an animal model of autosomal dominant polycystic kidney disease. Am J Pathol (2010) 0.97
Polycystic liver diseases. Dig Liver Dis (2010) 0.93
The utility of vitamin K3 (menadione) against pancreatic cancer. Anticancer Res (2008) 0.92
CDC25A: a rebel within the CDC25 phosphatases family? Anticancer Agents Med Chem (2008) 0.90
Is Cdc25 a druggable target? Anticancer Agents Med Chem (2008) 0.89
Regulation of Cdc25A half-life in interphase by cyclin-dependent kinase 2 activity. J Biol Chem (2003) 0.88
Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo. Int J Oncol (2005) 0.87
Inhibition of the development of metastases by dietary vitamin C:K3 combination. Life Sci (2004) 0.86
Independent mechanistic inhibition of cdc25 phosphatases by a natural product caulibugulone. Mol Pharmacol (2006) 0.86
An attempt to evaluate the effect of vitamin K3 using as an enhancer of anticancer agents. Biol Pharm Bull (2008) 0.85
Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy. Invest New Drugs (2005) 0.85
Activation of the Raf-1/MEK/Erk kinase pathway by a novel Cdc25 inhibitor in human prostate cancer cells. Prostate (2004) 0.85
H32, a non-quinone sulfone analog of vitamin K3, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating ERK. Cancer Biol Ther (2006) 0.83
Autoschizis: a novel cell death. Biochem Pharmacol (2002) 0.82
Vitamin K3 induces cell cycle arrest and cell death by inhibiting Cdc25 phosphatase. Eur J Cancer (1999) 0.81
Differential effects of two growth inhibitory K vitamin analogs on cell cycle regulating proteins in human hepatoma cells. Life Sci (2003) 0.80
Adverse events among medical patients after discharge from hospital. CMAJ (2004) 7.89
Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell (2006) 3.83
Strategies for improving attendance at medical grand rounds at an academic medical center. Mayo Clin Proc (2003) 3.71
Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol (2005) 3.65
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
Cryptosporidiosis. N Engl J Med (2002) 3.24
The transmembrane protein meckelin (MKS3) is mutated in Meckel-Gruber syndrome and the wpk rat. Nat Genet (2006) 3.19
Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat Genet (2011) 3.16
The Forkhead Box m1b transcription factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration. Proc Natl Acad Sci U S A (2002) 2.93
Requirement for CDK4 kinase function in breast cancer. Cancer Cell (2006) 2.92
A cellular micro-RNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection. J Biol Chem (2007) 2.89
Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol (2007) 2.71
Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology (2006) 2.68
Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia. Hum Mol Genet (2003) 2.55
Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease. Hum Mol Genet (2004) 2.47
Cholangiocyte cilia detect changes in luminal fluid flow and transmit them into intracellular Ca2+ and cAMP signaling. Gastroenterology (2006) 2.43
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
The mouse Forkhead Box m1 transcription factor is essential for hepatoblast mitosis and development of intrahepatic bile ducts and vessels during liver morphogenesis. Dev Biol (2004) 2.19
Assessment of renal hemodynamics and function in pigs with 64-section multidetector CT: comparison with electron-beam CT. Radiology (2007) 2.14
Characterization of PKD protein-positive exosome-like vesicles. J Am Soc Nephrol (2009) 2.13
Perceived impact of duty hours limits on the fragmentation of patient care: results from an academic health center. Am J Med (2005) 2.10
Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts. Liver Transpl (2013) 2.03
Isolation and characterization of cholangiocyte primary cilia. Am J Physiol Gastrointest Liver Physiol (2006) 1.92
Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to Cryptosporidium parvum via activation of NF-kappaB. J Immunol (2005) 1.88
Cortical microvascular remodeling in the stenotic kidney: role of increased oxidative stress. Arterioscler Thromb Vasc Biol (2004) 1.87
Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology (2008) 1.87
Eukaryotic initiation factor 6 is rate-limiting in translation, growth and transformation. Nature (2008) 1.85
Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia. Am J Physiol Gastrointest Liver Physiol (2010) 1.85
Akt induces beta-cell proliferation by regulating cyclin D1, cyclin D2, and p21 levels and cyclin-dependent kinase-4 activity. Diabetes (2006) 1.84
Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat. Gastroenterology (2003) 1.80
MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. J Immunol (2009) 1.76
Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest (2012) 1.74
Cyclic AMP regulates bicarbonate secretion in cholangiocytes through release of ATP into bile. Gastroenterology (2007) 1.73
Optimization-based reconstruction of sparse images from few-view projections. Phys Med Biol (2012) 1.72
Cholangiocyte cilia express TRPV4 and detect changes in luminal tonicity inducing bicarbonate secretion. Proc Natl Acad Sci U S A (2007) 1.72
Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation. Dev Cell (2006) 1.69
Algorithm-enabled low-dose micro-CT imaging. IEEE Trans Med Imaging (2010) 1.67
MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest (2008) 1.67
Quantitative assessment of hepatic fibrosis in an animal model with magnetic resonance elastography. Magn Reson Med (2007) 1.61
Ciliary and centrosomal defects associated with mutation and depletion of the Meckel syndrome genes MKS1 and MKS3. Hum Mol Genet (2009) 1.61
The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology (2009) 1.58
Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation (2002) 1.57
Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol (2012) 1.57
Identification, characterization, and localization of a novel kidney polycystin-1-polycystin-2 complex. J Biol Chem (2002) 1.56
Cholangiocyte primary cilia are chemosensory organelles that detect biliary nucleotides via P2Y12 purinergic receptors. Am J Physiol Gastrointest Liver Physiol (2008) 1.56
Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev (2002) 1.49
Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease. Am J Pathol (2004) 1.49
Antioxidant intervention attenuates myocardial neovascularization in hypercholesterolemia. Circulation (2004) 1.46
Research productivity of graduates from 3 physician-scientist training programs. Am J Med (2008) 1.44
Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat. Hepatology (2010) 1.41
Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology (2006) 1.40
Apical organelle discharge by Cryptosporidium parvum is temperature, cytoskeleton, and intracellular calcium dependent and required for host cell invasion. Infect Immun (2004) 1.40
NFkappaB p50-CCAAT/enhancer-binding protein beta (C/EBPbeta)-mediated transcriptional repression of microRNA let-7i following microbial infection. J Biol Chem (2009) 1.40
A polycystin-1 multiprotein complex is disrupted in polycystic kidney disease cells. Mol Biol Cell (2004) 1.39
Simvastatin prevents coronary microvascular remodeling in renovascular hypertensive pigs. J Am Soc Nephrol (2007) 1.38
Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology (2012) 1.38
Representing complexity well: a story about teamwork, with implications for how we teach collaboration. Med Educ (2012) 1.38
The use of microcomputed tomography to study microvasculature in small rodents. Am J Physiol Regul Integr Comp Physiol (2002) 1.36
Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol Cell Biol (2004) 1.35
Thyroid hormone regulates the cell cycle inhibitor p27Kip1 in postnatal murine Sertoli cells. Endocrinology (2003) 1.35
Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. Am J Pathol (2008) 1.34
Small-animal molecular imaging methods. J Nucl Med (2010) 1.32
Cdk4 promotes adipogenesis through PPARgamma activation. Cell Metab (2005) 1.31
Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity. FASEB J (2004) 1.30
Cholangiocyte primary cilia in liver health and disease. Dev Dyn (2008) 1.29
Structural morphology of renal vasculature. Am J Physiol Heart Circ Physiol (2006) 1.29
Effects of loss of steroid receptor coactivator-1 on the skeletal response to estrogen in mice. Endocrinology (2003) 1.28
Functional anatomy and hemodynamic characteristics of vasa vasorum in the walls of porcine coronary arteries. Anat Rec A Discov Mol Cell Evol Biol (2003) 1.27
Validation of image-based method for extraction of coronary morphometry. Ann Biomed Eng (2008) 1.27
Expression and localization of aquaporin water channels in rat hepatocytes. Evidence for a role in canalicular bile secretion. J Biol Chem (2002) 1.27
Analysis of the polycystins in aortic vascular smooth muscle cells. J Am Soc Nephrol (2003) 1.27
Evaluation of conventional imaging performance in a research whole-body CT system with a photon-counting detector array. Phys Med Biol (2016) 1.26
Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conference. J Pediatr (2006) 1.26
Cryostatic micro-computed tomography imaging of arterial wall perfusion. Scanning (2002) 1.26
Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation. Am J Pathol (2002) 1.24
Quantitative analysis of interconnectivity of porous biodegradable scaffolds with micro-computed tomography. J Biomed Mater Res A (2004) 1.23
Proteolytic cleavage and nuclear translocation of fibrocystin is regulated by intracellular Ca2+ and activation of protein kinase C. J Biol Chem (2006) 1.22
Cryptosporidium parvum invasion of biliary epithelia requires host cell tyrosine phosphorylation of cortactin via c-Src. Gastroenterology (2003) 1.21
Poly(propylene fumarate) bone tissue engineering scaffold fabrication using stereolithography: effects of resin formulations and laser parameters. Biomacromolecules (2007) 1.20
Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD. Gastroenterology (2010) 1.20
Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Res (2007) 1.20
Imaging the aqueous humor outflow pathway in human eyes by three-dimensional micro-computed tomography (3D micro-CT). Exp Eye Res (2010) 1.20
Antioxidant intervention prevents renal neovascularization in hypercholesterolemic pigs. J Am Soc Nephrol (2004) 1.19